Fluoroquinolone use varies significantly based on provider a
Fluoroquinolone use decreased between 2015 and 2016 due in part to FDA advisories. However, their use still varies significantly based on provider age and other characteristics, according to a study.

The researchers used IQVIA’s National Disease and Therapeutic Index to quantify adult outpatient fluoroquinolone use. According to the study, the researchers used descriptive statistics and segmented regression to report trends and quantify the varied use before and after the FDA’s 2016 alerts.

The study demonstrated that between 2015 and 2019, fluoroquinolone use decreased by 36.5%, with 18.7 million treatment visits in 2015 and 13.7 million treatment visits in 2019. Further analysis revealed that annual use declined by 78% for respiratory, 31% for urogenital and 31% for gastrointestinal conditions. Additionally, there was a 191% decrease in use among providers aged 44 years and younger compared with a 34% decrease among providers aged 55 to 64 years and a 2% increase among providers 65 years and older.

According to the study, before the 2016 FDA advisories, there were approximately 4.8 million fluoroquinolone treatment visits per yearly quarter, which declined by 641,035 visits after the FDA’s 2016 advisories. There was a statistically significant decline of approximately 45,000 visits per yearly quarter after the advisories.

“The dissimilarities in fluoroquinolone utilization by prescriber characteristics suggests underlying differences in attitudes, knowledge, clinical census, and prescribing behaviors,” the authors wrote. “Identifying and targeting specific segments of prescribers may further help to reduce fluoroquinolone overuse.”

Source: https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofab538/6409253